• Scientists can now search, understand and act on complex R&D data in natural language by leveraging leading LLM capabilities within the Signals One platform
• Governed data and ontology-driven scientific context support reliable, traceable results across workflows
• Native agentic framework turns connected data and knowledge into task-ready insights for scientists

WALTHAM, Mass.--(BUSINESS WIRE)--Jun. 22, 2026-- Revvity, Inc. (NYSE: RVTY) announced the continued evolution of artificial intelligence across its Revvity Signals software business with new and expanding AI capabilities. Built natively into the Signals One™ platform, new capabilities from Signals AI help scientists transform connected R&D data into understanding, decisions and action using natural language within their existing workflows.

As scientific organizations generate increasing volumes of data across experiments, instruments, applications and systems, the challenge is no longer collecting information, but rather, turning that information into understanding and action. Signals AI introduces a new intelligence layer into the Signals One platform, allowing scientists to engage directly with connected R&D knowledge and dynamically recast it for any purpose. Signals AI helps researchers transform existing knowledge into the form needed to drive decisions and execution.

“The addition of the Signals AI capabilities within Revvity’s Signals One platform reflects a fundamental shift in how scientists work with R&D knowledge,” said Kevin Willoe, president of Revvity Signals Software. “For decades, scientific software has organized information into predefined applications, workflows and dashboards. The new features Signals AI introduces provide a new model where researchers can engage directly with organizational knowledge, ask questions in natural language and dynamically transform information. By combining the adaptive reasoning of modern AI with trusted scientific intelligence, Revvity’s Signals AI helps organizations accelerate insight without compromising scientific rigor.”

Grounded in structured scientific data, domain ontologies and validated scientific algorithms, Signals AI delivers traceable, scientifically relevant responses through natural language and interactive views of molecules, sequences, experimental results and connected knowledge. This helps scientists understand, validate and act in context while maintaining scientific rigor.

This integrated intelligence transforms scientific software from a system of record into a system of scientific understanding, helping researchers move from data to insight, and from insight to action, faster than ever before. Select capabilities of Signals AI are available today, with additional capabilities expected to be released and enhanced in the coming weeks.

About Revvity

At Revvity, "impossible" is inspiration, and "can't be done" is a call to action. Revvity provides health science solutions, technologies, expertise, and services that deliver complete workflows from discovery to development, and diagnosis to cure. Revvity is revolutionizing what's possible in healthcare, with specialized focus areas in translational multi-omics technologies, biomarker identification, imaging, prediction, screening, detection and diagnosis, informatics and more.

With 2025 revenue of $2.9 billion and approximately 11,000 employees, Revvity serves customers across pharmaceutical and biotech, diagnostic labs, academia and governments. It is part of the S&P 500 index and has customers in more than 160 countries.

Stay updated by following our Newsroom, LinkedIn, X, YouTube, Facebook and Instagram.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260622242972/en/

Investor Relations:
Steve Willoughby
steve.willoughby@revvity.com

Media Relations:
Chet Murray
(781) 462-5126
chet.murray@revvity.com

Source: Revvity